beeldscherm schreef op 15 september 2018 12:39:
[...]
kijk, die indruk krijg ik ook steevast, zekers ook na het laatste van Amicus Therapeutics,
Amicus Therapeutics announces that its AT-GAA pompe disease program was not allowed to file for accelerated approval.
dat de fda het nog niet goedkeurd heeft m.i ook te maken wat ik in mijn vorige post neerzet van Scott Gottlieb dat ze meer naar recom. med gaan kijken
www.fda.gov/NewsEvents/Newsroom/Press.....To help address these challenges, the FDA is working to help develop more effective cell lines that can be better scaled through continuous manufacturing.
We’re also looking at how we develop a more robust recombinant vaccine manufacturing process to increase yield, while reducing cost.
Continuous manufacturing holds great promise for both cell-based and recombinant vaccines, because supply could be more easily ramped up on short notice.